Prem K. Premsrirut, MD, PhD, Founder, Chief Executive Officer

Dr. Premsrirut is an expert in the development and use of RNAi transgenic mice for fast and flexible validation and toxicity assessment of candidate genes targets in vivo. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice and pioneered a novel approach for the generation of “speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer.

Dr. Premsrirut was an MD/PhD fellow at SUNY Stony Brook School of Medicine. She received her Ph.D. in genetics and cancer biology following her training in the laboratory of Dr. Scott Lowe at Cold Spring Harbor Laboratory. Her work focused on the development of transgenic mouse models to study the effects of tumor maintenance on lung cancer using RNA interference. She received her M.D. from SUNY Stony Brook and Winthrop University Hospital, exploring the challenges of patient care and utilizing her broad knowledge to propose health care solutions. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. She previously worked in the lab of Dr. Ravi Iyengar at Mount Sinai School of Medicine, where she studied the downstream effects heterotrimeric G-proteins coupled to muscarinic, dopamine and adrenergic receptors in order to gain an understanding of the signal transduction pathways that play a role in opioid addiction and neuronal development.

For More Detail